Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

Catherine M. Diefenbach, MD, associate professor, Department of Medicine, clinical director of lymphoma, NYU Langone Medical Center, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Fifty-six patients were enrolled in the phase Ib/II GO29834 trial, which treated heavily pretreated patients with follicular lymphoma. The patient population had a median of 3 prior lines of therapy; 50% were refractory to last line of prior regimen, and 25% had progression of diease within 2 years of their initial chemotherapy, which is an independent negative prognostic factor. At the end of the trial 39 patients were evaluated for efficacy ofpolatuzumab vedotin plus obinutuzumab and lenalidomide.

All patients had ≥1 adverse event (AE). The most common grade 3/4 AEs were myelosuppression; however, with growth factor support, most patients were able to continue on therapy. Eleven percent incidence of neutropenic fever, which Diefenbach theorizes is due to the patients being heavily pretreated.